The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn). The deal comprises cash and cash equivalents worth $14m (Rs1.15bn) in the acquired business representing an enterprise value of $231m (Rs18.85bn).
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Holding a presence in the cosmetic dermatology sector, Curatio’s portfolio comprises more than over 50 brands that are commercialised in India. The portfolio includes brands such as Tedibar, Atogla, Spoo, B4 Nappi and Permite.
Torrent Pharmaceuticals director Aman Mehta said: “We are delighted to enter into this deal with Curatio.
“The acquisition offers Torrent the opportunity to enhance its presence in dermatology with a differentiated portfolio and is a strong strategic fit.
“Curatio has built a commendable set of high market share brands in cosmetic and pediatric dermatology that we look forward to adding to our product offerings.”
Subject to necessary conditions, the deal is anticipated to conclude in a month.
A flagship company of the Torrent Group, Torrent Pharmaceuticals is a speciality-focused firm with more than 74% of its revenue from chronic and sub-chronic therapies in India.
Having a presence in 40 countries, the company has seven manufacturing plants. Among these facilities, four are approved by the US Food and Drug Administration (FDA).
Torrent R&D infrastructure employs over 800 scientists.
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.